PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene

Cancer Research

Volumn 66, Issue 20, 2006, Pages 9809-9817

  Mayes, Debra A ^a   Hu, Yuanjie ^a   Teng, Yue ^a   Siegel, Eric ^a   Wu, Xiaosong ^a   Panda, Kishori ^a   Tan, Fang ^c   Yung, W K Alfred ^c   Zhou, Yi Hong ^a,b,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TRANSCRIPTION FACTOR PAX6;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER INHIBITION; CANCER INVASION; CARCINOGENICITY; CELL INVASION; CONTROLLED STUDY; DNA BINDING; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; EYE PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HOMEODOMAIN PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PAIRED BOX TRANSCRIPTION FACTORS; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33750559852     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3877     Document Type: Article

References (44)

1. CBTRUS. Statistical report: primary brain tumors in the United States, 1997-2001. Central Brain Tumor Registry of the United States; 2004.
2. Kleihues P, Cavenee WK. Pathology and genetics of tumor of the nervous system. Lyon (France): IARC Press; 2000. p. 9-54.
3. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989;7:165-77.
4. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
5. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
6. Zhou YH, Wu X, Tan F, et al. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 2005;71:223-9.
7. Zhou YH, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003; 9:3369-75.
8. Callaerts P, Halder G, Gehring WJ. PAX-6 in development and evolution. Annu Rev Neurosci 1997;20:483-532.
9. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet 2002;18:41-7.
10. Stoykova A, Grass P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994;14:1395-412.
11. Nacher J, Varea E, Blasco-Ibanez JM, et al. Expression of the transcription factor Pax6 in the adult rat dentate gyrus. J Neurosci Res 2005;81:753-61.
12. Collinson JM, Chanas SA, Hill RE, et al. Corneal development, limbal stem cell function, and corneal epithelial cell migration in the Pax6(+/-) mouse. Invest Ophthalmol Vis Sci 2004;45:1101-8.
13. Nomura T, Osumi N. Misrouting of mitral cell progenitors in the Pax6/small eye rat telencephalon. Development 2004;131:787-96.
14. Chapouton P, Gartner A, Gotz M. The role of Pax6 in restricting cell migration between developing cortex and basal ganglia. Development 1999;126:5569-79.
15. Jimenez D, Lopez-Mascaraque L, de Carlos JA, et al. Further studies on cortical tangential migration in wild type and Pax-6 mutant mice. J Neurocytol 2002;31:719-28.
16. Engelkamp D, Rashbass P, Seawright A, et al. Role of Pax6 in development of the cerebellar system. Development 1999;126:3585-96.
17. Hamasuna R, Kataoka H, Moriyama T, et al. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 1999;82:274-81.
18. Qin H, Moellinger JD, Wells A, et al. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-α and IFN-γ. J Immunology 1998;161:6664-73.
19. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974-82.
20. Giannelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.
21. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
22. Dong J, Opresko LK, Dempsey PJ, et al. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A 1999;96:6235-40.
23. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001;52:401-10.
24. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
25. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-28.
26. Rooprai HK, Van Meter T, Rucklidge GJ, et al. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours. Int J Oncol 1998;13:1153-7.
27. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-92.
28. Raithatha SA, Muzik H, Rewcastle NB, et al. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-oncol 2000;2:145-50.
29. Levicar N, Nutall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir (Wien) 2003;145:825-38.
30. Zhou YH, Hess RK, Liu L, et al. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro-oncol 2005;7:485-94.
31. Ishii N, Maier D, Merlo A, et al. Frequent coalterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
32. Ke LD, Shi YX, Im SA, et al. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 2000;6:2562-72.
33. Zheng JB, Zhou YH, Maity T, et al. Activation of the human PAX6 gene through the exon 1 enhancer by transcription factors SEF and Sp1. Nucleic Acids Res 2001;29:4070-8.
34. Tang HK, Chao LY, Saunders GF. Functional analysis of paired box missense mutations in the PAX6 gene. Hum Mol Genet 1997;6:381-6.
35. Nirmala C, Jasti SL, Sawaya R, et al. Effects of radiation on the levels of MMP-2, MMP-9 and TIMP-1 during morphogenic glial-endothelial cell interactions. Int J Cancer 2000;88:766-71.
36. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990;265:11077-82.
37. Zhou YH, Zheng JB, Gu X, et al. Novel PAX6 binding sites in the human genome and the role of repetitive elements in the evolution of gene regulation. Genome Res 2002;12:1716-22.
38. Prosser J, van Heyningen V. PAX6 mutations reviewed. Hum Mutat 1998;11:93-108.
39. Tang HK, Singh S, Saunders GF. Dissection of the transactivation function of the transcription factor encoded by the eye developmental gene PAX6. J Biol Chem 1998;273:7210-21.
40. Epstein J, Cai J, Glaser T, et al. Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. J Biol Chem 1994;269:8355-61.
41. Zhou Y-H, Glass T, Yung WKA. PAX6 down-regulate the expression of PDGFRA and MCP-1 genes in glioblastoma cells. Neuro-oncol 2001;3:312.
42. Koul D, Parthasarathy R, Shen R, et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 2001;20:6669-78.
43. Wang H, Shen W, Huang H, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003;63:4315-21.
44. Sivak JM, Mohan R, Rinehart WB, et al. Pax-6 expression and activity are induced in the reepithelializing cornea and control activity of the transcriptional promoter for matrix metalloproteinase gelatinase B. Dev Biol 2000;222:41-54.